Literature DB >> 18322170

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

Micah J Benson1, Stacey R Dillon, Emanuela Castigli, Raif S Geha, Shengli Xu, Kong-Peng Lam, Randolph J Noelle.   

Abstract

Memory B (B(MEM)) cells and long-lived bone marrow plasma cells (BM-PCs) persist within local environmental survival niches that afford cellular longevity. However, the factors supporting B(MEM) cell survival within the secondary lymphoid organs and allowing BM-PC persistence in the bone marrow remain poorly characterized. We report herein that long-lived B(MEM) cell survival and function are completely independent of BAFF (B cell-activating factor of the TNF family) or APRIL (a proliferation-inducing ligand). Thus, B(MEM) cells represent the only mature B2 lineage subset whose survival is independent of these ligands. We have previously shown that the TNFR family member receptor BCMA (B cell maturation Ag) is a critical survival receptor for BM-PC survival in vivo. We identify in this study the ligands critical for BM-PC survival and show that either BAFF or APRIL supports the survival of BM-PCs in vivo. These data define the BAFF/APRIL-dependent and -independent components of long-lived humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322170     DOI: 10.4049/jimmunol.180.6.3655

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  190 in total

Review 1.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 2.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 3.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

4.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Authors:  William Stohl; Falk Hiepe; Kevin M Latinis; Mathew Thomas; Morton A Scheinberg; Ann Clarke; Cynthia Aranow; Frank R Wellborne; Carlos Abud-Mendoza; Douglas R Hough; Lilia Pineda; Thi-Sau Migone; Z John Zhong; William W Freimuth; W Winn Chatham
Journal:  Arthritis Rheum       Date:  2012-07

5.  Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.

Authors:  Abby Jones Weldon; Ioana Moldovan; Marven G Cabling; Elvin A Hernandez; Sheri Hsu; Jennifer Gonzalez; Andrea Parra; Abigail Benitez; Nasim Daoud; Keith Colburn; Kimberly J Payne
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

Review 6.  Innate signaling networks in mucosal IgA class switching.

Authors:  Alejo Chorny; Irene Puga; Andrea Cerutti
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

7.  Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Diane E Griffin
Journal:  J Gen Virol       Date:  2016-09-22       Impact factor: 3.891

8.  B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells.

Authors:  V Gorbacheva; K Ayasoufi; R Fan; W M Baldwin; A Valujskikh
Journal:  Am J Transplant       Date:  2014-12-12       Impact factor: 8.086

9.  Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis.

Authors:  Talibah U Metcalf; Victoria K Baxter; Voraphoj Nilaratanakul; Diane E Griffin
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 10.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.